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PV tree was developed where pressure was modeled as the product of chain- 
bar elastanca and volume. An analytical solution of the unsteady Bernoulli 
equation was achieved by lineadzing the equation. The solution equation 
consisted of a cosine function, which captures visa largo, and a sine function, 
which captures vis a fmnte. Time-varying systolic PV velocity, ut(t) -cms, is 
a function of the following variables: total atrial suction created by atrial re- 
laxation (z~Paf -- mmHg) and mitral annular descent (&Pm¢ - mmHg), atrial 
(Ea - mmH~rco) and PV alastance (Epv), net atrial-- PV elactance (Enet = Ea 
+ Ew), the average rate of PV tree replenishment from the capillaries (QL -- 
cm31s), total PV cross*sectional rea at the atrial junction (A-  cm2), and PV 
inertanca (pLea -- g/cm2). This model found that tl'e peak velocity and inte- 
gral of systolic PV flow increased as atrial suction and PV tree replenishment 
increased, but decreased as atrial and PV elastanca, PV inedanca, and PV 
crsss-sectional area increased. Also, this model predicts aspects of systolic 
PV flow that are consistent with expedmental and clinical observations: (i) 
the vis a tergo component of systolic PV flow is minimized by compliant PVs 
(small PV elastanca); (if) atrial events, so-called visa fronte, dominate the 
magnitude of systolic PV flow; (iii) systolic PV flow is reduced by elevations in 
atrial pressure but onlywhan compliance is also reduced; (iv) compensatory 
increases in atrial suction and PV tree replenishment may overcome reduc- 
tions in systolic PV flow due to elevated atdal pressures; (v) PV inertanca nd 
area are important dP.terminants of the magnitude and timing of PV flow. 
U( t )=~ 1-cos  (t) + ~ sin (t) 
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~ Differential Sympathetic of  Muscle Neural Control  
Oxygenat ion in Resting and Exercising Human 
Skeletal Muscle 
Jim Hansen, Gall D. Thomas, William J. Parsons, Ronald G. Victor. UT 
Southwestern, Dallas, Texas 
Although the muscle metaboreflex triggers increases in muscle sympathetic 
nerve activity (SNA) targeted to beth resting and exercising human skeletal 
muscle, our recent rat studies advance the hypothesis that the vasocon- 
striction normally evoked by increased muscle SNA is salectively attenuated 
in the contracting muscle, thereby optimizing muscle perfusion. The abil- 
ity to continuously measure muscle oxygenation (cytochrome a,a3 redox 
state and tissue oxygen stores (t(HbO~ + MbO~)) in exercising muscle with 
near infrared spectroscopy while simultaneously measudng muscle SNA 
(micronecrography) provided a new opportunity tO test this hypothesis in 
humans. Specitically, we asked if a reflex increaSe in muscle SNA decreases 
muscle oxygenation i  resting, but not in exercising muscle. In 10 healthy hu- 
mans, we measured oxygenation in forearm muscle during reflex increases 
in muscle SNA evoked by non-hypotenslve tower body negative pressure 
(LBNP, -20 mmHg) at rest and dudng mild rhythmic handgdp (5 rain 20% of 
maximum). At re~', LBNP increased muscle SNA by 292 4. 72% (mean -*- SE) 
and decreased t(HbO2 + MbO2) by 10 4. 1% (p < 0.05) of the maximal de- 
crease (assessed with complete forearm ischemia). This decrease in t(HbO 
2 + MbO2) in the resting forearm was sympathetically-mediated because 
it was abolished by local sympathetic block with bretylium. Handgdp alone 
caused no change in muscle SNA, but rapidly decreased t(HbO2 + MbO2) 
to a steady state 28 4- 4% below baseline. Importantly, when superimposed 
on handgdp, LBNP increased MSNA by 305 4. 59%, but now had no effect 
on tissue oxygenation in the exercising muscle (zit(HbO.a ÷ MbO2) = +0.4 
4- 3%, p = ns). These data provide direct evidence in humans that reflex 
sympathetic activation decreases oxygenation in resting, but not in exercis- 
ing human skeletal muscle. This mechanism would optimize oxygenation of 
active muscle when the muscle metaboreflex iS engaged. 
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~ T h e  Pharmace-Genctice of  Congenital  Cardiac 
Defects in Retinoic Acid Receptor Oeflelent Mouse 
Embryos 
Henry M. Sucov, Vicky LaMorte, Jiangming Luo, Vincent Giguere, Ronald 
M. Evans. Univ. of Southern California SchooI of Medicine, Los Angeles, CA 
Germline mutations in several of the genes which encode receptors for the 
signaling molecule retinoic acid (PA) have been previously established in 
mica. Cardiac phenotypes which emerge in mutant embryos include defects 
in the ventricular chamber, conus, truncos, and aortic arch artedes. Based 
on new experimental and theoretical observations, the following conclusions 
have been drawn concerning the pharmacology of RA receptor function in 
mediating complex aspects of cardiac morphogenasis: (1) the level of func- 
tional receptor, known to be a heterodimsr of RAR and RXR monomers, is 
dictated by equilibrium considerations; (2) in the tissue involved in septation 
of the tmncus, the levels of RAR and RXR monomers are roughly compa- 
r'abte, explaining the emergence of persistent truncus artedosus only after 
combined mutation of PAR and RXR; (3) target genes of RA action critical in 
the morphogansSiS of the ventricular chamber contain receptor binding sites 
in their promoters of moderate, rather than high, affinity; this is also likely 
to be true in most other cases of RA action; (4) differentiation of the conus 
cushions is a significantly different response to RA than is morphoganesis of 
either the truncus or the vantricutar chamber, in that the conus is sensitive to 
beth insufficient or excess RA, whereas the tmncus and ventdcular chamber 
are sensitive to only RA deficiency; (5) the pharmacology of the RA recep- 
tors may in some cases make it possible to reverse the consequences of 
receptor mutation by treatment with exogenous RA; this approach was not 
successful in rescuing the hypoplastic ventricular phenotype, indicating that 
receptor mutation also supresses the inducible RA response to below the re- 
quired threshold in this tissue. These conclusions make testable predictions 
concerning the molecular mechanisms of normal and pathological cardiac 
morphoganesis, which will be evaluated through future molecular analysis. 
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I -4-~- '~ Localization of  the Gene for  Familial Id iopathic 
Dilated Card iomyopathy to Chromosome lq32  
Jean-Bernard Durand, Linda L. Bechinsld, Lisa Bailing, Grazyna 
Z. Czemuszewicz, Antoine B. Abchee, Qun Tec Yu, Rite Hill, Jonah Ifegwu, 
A.J. Marian, Ramon Brugada, Staven Daiger, Jane M. Gregoritch, 
Jeff Anderson, Miguel Quifiones, Jeffrey A. Towbin, Robert Roberts. Baylcr 
College of MedicirTe, I~ousten, Texas 
Cardiac failure is the tastast growing cardiovascular condition in the Western 
wodd with over 400,000 new cases per year in the U.S. The cost in the U.S. 
for cardiac transplantation alone is over $200 million and for all cardiac failure 
over $10 billion. Dilated cardiomyopathy (DCM), the most common cause 
of heart failure, is a pdmary cardiac disease charactedzed by vantricular di- 
latation and impaired systolic contraction and manifested clinically by either 
sudden death or pump failure. The cause for DCM is unknown (idiopathic, 
IDCM) with 20% estimated to be inherited. To identify the genetic defect for 
IDCM one must first map the chromosomal ocus. Thus, we studied a four 
generation kindred with ten members having IDCM, detected by echecardiog- 
raphy. IDCM segregated as a highly panetrant autosomal dominant disorder. 
A genome search was performed using short tandem repeat pofymorphic 
(STRP) markers. Two-point and multi-point linkage analysis was conducted 
assuming ponetranca to be 00%. Approximately 90% of the genome was ex- 
cluded by multi.point analysis of > 400 mad~ers. Peak led score of 5.78 was 
obtained at the marker DIS414 with t) = 0% recombination. Peak multi-point 
Iod score, also at D1S414, was 6.37. Haplotype analysis identified recombi- 
nation events between the disease gane and polymoq0hic markers in seven 
individuals. The region of lq common to all ten affected individuals is flanked 
by markers D1S249 and D1 $549 which are approximately 20 cM apart. Rea- 
sonable candidates including myosin-binding protein-H, MEF-2D, renin and 
plasma membrane calcium transporting ATPase, are known to be localized 
to this region and studies are now underway using the positional candidate 
approach to isolate and identify the responsible gane. Identification of the ge- 
netic defect should elucidate the molecular basis for familial DCM, providing 
a means for precise diagnosis and screening of asymptomaflc individuals at 
risk pdor to the development of this disease, which is a necessary step in our 
ultimate goal of providing effective prevention and treatment of this disease. 
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~ A  Functional Role fo r  Endothelin-1 in 
Norepinephrine- lnduced Ventricular Hypert rophy in 
Vivo and in Vitro 
Samer Kaddoura. MRCP, National Heart & Lung Institute, London, United 
Kingdom 
Background Endothelin-1 (ET-1) has potent effects upon call growth. We 
tested the hypothesis that endogenous ET-I plays a functional role in nore- 
pinaphfine (NE)-induced ventdcular hypertrophy by studying physical indices 
